Clinical outcome of treatment with a combined regimen of decitabine and aclacinomycin/cytarabine for patients with refractory acute myeloid leukemia

Annals of Hematology

Volumn 91, Issue 12, 2012, Pages 1879-1886

  Song, Lu Xi ^a   Xu, Li ^a   Li, Xiao ^a   Chang, Chun Kang ^a   Zhang, Yi ^a   Wu, Ling Yun ^a   He, Qi ^a   Zhang, Qing Xia ^a   Li, Xiang ^b  

^a SHANGHAI JIAO TONG UNIVERSITY AFFILIATED SIXTH PEOPLE S HOSPITAL   (China)

^b Fred Hutchinson Cancer Research Center   (United States)

Author keywords

Aclacinomycin; Acute myeloid leukemia (AML); Cytarabine; Decitabine (DAC); Refractory

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ACLACINOMYCIN; ANTHRACYCLINE; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTARABINE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; HOMOHARRINGTONINE; IDARUBICIN; MITOMYCIN; PIRARUBICIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALLOGENEIC PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CANCER MORTALITY; CANCER PATIENT; CANCER SURVIVAL; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DNA METHYLATION; DRUG EFFICACY; DRUG MEGADOSE; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; LEUKEMIA CELL; LEUKEMIA RELAPSE; LEUKEMIA REMISSION; LOW DRUG DOSE; MALE; MALIGNANT TRANSFORMATION; MYELODYSPLASTIC SYNDROME; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; SURVIVAL TIME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACLARUBICIN; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AZACITIDINE; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYTARABINE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; LEUKEMIA, MYELOID, ACUTE; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; RECURRENCE; REMISSION INDUCTION; SURVIVAL ANALYSIS; TUMOR CELLS, CULTURED; YOUNG ADULT;

EID: 84870983498     PISSN: 09395555     EISSN: 14320584     Source Type: Journal    
DOI: 10.1007/s00277-012-1550-y     Document Type: Article

References (18)

1. Lowenberg B, Downing JR, Burnett A (1999) Acute myeloid leukemia. N Engl J Med 341:1051-1062
2. Kern W, Aul C, Maschmeyer G et al (1998) Superiority of highdose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia 12:1049-1055
3. Karanes C, Kopecky KJ, Head DR et al (1999) A phase III comparison of high dose ARA-C (HIDAC) versus HIDAC plus mitoxantrone in the treatment of first relapsed or refractory acute myeloid leukemia Southwest Oncology Group Study. Leuk Res 23:787-794
4. Liu Yin JA, Wheatley K, Rees JK, Burnett AK, UK MRC Adult Leukemia Working Party (2001) Comparison of 'sequential' versus 'standard' chemotherapy as re-induction treatment, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Br J Haematol 113:713-726
5. List AF, Kopecky KJ, Willman CL et al (2001) Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood 98:3212-3220
6. Sorm F, Vesely J (1968) Effect of 5-aza-20-deoxycytidine against leukemic and hemopoietic tissues in AKR mice. Neoplasma 15:339-343
7. Issa JP, Kantarjian HM, Kirkpatrick P (2005) Azacitidine. Nat Rev Drug Discov 4:275-276
8. Chowdhury S, Seropian S, Marks PW (2009) Decitabine combined with fractionated gemtuzumab ozogamicin therapy in patients with relapsed or refractory acute myeloid leukemia. Am J Hematol 84:599-600
9. Willemze R, Archimbaud E, Muus P (1993) Preliminary results with 5-aza-2′-deoxycytidine (DAC)-containing chemotherapy in patients with relapsed or refractory acute leukemia. The EORTC Leukemia Cooperative Group. Leukemia 7(Suppl 1):49-50
10. Sartorelli AC (1985) The 1985 Walter Hubert lecture. Malignant cell differentiation as a potential therapeutic approach. Br J Cancer 52:293-302
11. Qin T, Youssef EM, Jelinek J et al (2007) Effect of cytarabine and decitabine in combination in human leukemic cell lines. Clin Cancer Res 13:4225-4232
12. ESMO (2005) Minimum clinical recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Ann Oncol 16:i48-i49
13. Cheson BD, Bennett JM, Kopecky KJ et al (2003) Revised recommendations of the international working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 21:4642-4649
14. Herman JG, Graff JR et al (1996) Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands. Proc Natl Acad Sci USA 93:9821-9826
15. Cashen AF, Shah AK, Todt L et al. (2008) Pharmacokinetics of decitabine administered as a 3-h infusion to patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Cancer Chemother Pharmacol 61:759-766
16. Scheithauer W, Clark GM, Salmon SE, Dorda W, Shoemaker RH, Von Hoff DD (1986) Model for estimation of clinically achievable plasma concentrations for investigational anticancer drugs in man. Cancer Treat Rep 70:1379-1382
17. Kohrt HE, Patel S, Ho M et al (2010) Second-line mitoxantrone, etoposide, and cytarabine for acute myeloid leukemia: a singlecenter experience. Am I Hematol 85:877-881
18. Hollenbach PW, Nguyen AN, Brady H et al. (2010) A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines. PLoS ONE 5:e9001